Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance
- PMID: 10378514
Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance
Abstract
High levels of urokinase-type plasminogen activator receptor (uPAR) are expressed in various types of cancer. Recent studies showed that cancer patients may have increased levels of soluble (s)uPAR in their serum. In the present study, we show that urine samples from healthy volunteers contain measurable amounts of suPAR. suPAR/creatinine levels from healthy controls showed only little variation over the day and were even stable during a month of continued monitoring. Importantly, urinary suPAR/creatinine levels were highly correlated with serum suPAR concentrations. Urinary suPAR levels were elevated in patients with different types of cancer. Interestingly, part of the urinary suPAR seemed to be present in a cleaved form, as has been found in tumor tissue extracts. Together with the recently established, cell migration-promoting effect of certain cleaved fragments of suPAR, the present data suggest that the measurement of urinary suPAR and/or its cleaved forms might have clinical implications.
Similar articles
-
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice.Thromb Haemost. 2004 Feb;91(2):403-11. doi: 10.1160/TH03-06-0351. Thromb Haemost. 2004. PMID: 14961171
-
Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.Gynecol Oncol. 2001 Sep;82(3):523-31. doi: 10.1006/gyno.2001.6324. Gynecol Oncol. 2001. PMID: 11520150
-
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.Cancer Res. 1998 May 1;58(9):1843-9. Cancer Res. 1998. PMID: 9581823
-
Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.Gynecol Oncol. 1996 Feb;60(2):264-70. doi: 10.1006/gyno.1996.0036. Gynecol Oncol. 1996. PMID: 8631549 Review.
-
Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer.Med Res Rev. 2004 Jan;24(1):13-39. doi: 10.1002/med.10054. Med Res Rev. 2004. PMID: 14595671 Review.
Cited by
-
Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection.J Intern Med. 2014 Oct;276(4):387-95. doi: 10.1111/joim.12257. Epub 2014 May 14. J Intern Med. 2014. PMID: 24717117 Free PMC article.
-
Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins.Biomark Cancer. 2016 Sep 27;8:119-133. doi: 10.4137/BIC.S38542. eCollection 2016. Biomark Cancer. 2016. PMID: 27721658 Free PMC article. Review.
-
Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.Front Immunol. 2021 Dec 2;12:780641. doi: 10.3389/fimmu.2021.780641. eCollection 2021. Front Immunol. 2021. PMID: 34925360 Free PMC article. Review.
-
Urinary suPAR: a non-invasive biomarker of infection and tissue inflammation for use in studies of large free-ranging mammals.R Soc Open Sci. 2020 Feb 12;7(2):191825. doi: 10.1098/rsos.191825. eCollection 2020 Feb. R Soc Open Sci. 2020. PMID: 32257339 Free PMC article.
-
Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis.Sci Rep. 2016 Dec 19;6:39481. doi: 10.1038/srep39481. Sci Rep. 2016. PMID: 27991579 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical